SCHEMBL6184529

SCHEMBL6184529

CN(Cc1cccc(Br)c1)c1ccccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.49
EPAS1 Q99814 1/20 0.49
PYCR1 P32322 1/20 0.47
ADRA2C P18825 2/20 0.46
CHRM2 P08172 2/20 0.46
ADRA2A P08913 2/20 0.46
DRD1 P21728 2/20 0.46
SLC6A2 P23975 2/20 0.46
SLC6A4 P31645 2/20 0.46
ADRA1A P35348 2/20 0.46
SLC6A3 Q01959 2/20 0.46
KCNH2 Q12809 2/20 0.46
ADRA2B P18089 1/20 0.46
HTR2A P28223 1/20 0.46
HRH1 P35367 1/20 0.46
OPRK1 P41145 1/20 0.46
TAAR1 Q96RJ0 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
LMNA P02545 2/20 0.44
MAPK1 P28482 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4747138 0.82 CHRM2 (0.63) HIF1AEPAS1ADRA2CCHRM2ADRA2A
SCHEMBL30280516 0.82 CHRM2 (0.72) ADRA2CCHRM2ADRA2ADRD1SLC6A2
SCHEMBL9447012 0.82 HIF1A (0.49) HIF1AEPAS1ADRA2CCHRM2ADRA2A
SCHEMBL9447031 0.76 CYP1A2 (0.54) HIF1AEPAS1PYCR1LMNAALDH1A1
SCHEMBL7667745 0.76 PYCR1 (0.53) HIF1APYCR1CHRM2TAAR1SMN1; SMN2
SCHEMBL8805352 0.75 CHRNB2 (0.59) HIF1AEPAS1ADRA2CCHRM2ADRA2A
SCHEMBL14220155 0.74 MEN1 (0.56) HIF1AEPAS1ADRA2CCHRM2ADRA2A
SCHEMBL28707159 0.74 CKS1B (0.54) HIF1APYCR1DRD1TAAR1SMN1; SMN2
SCHEMBL30725788 0.74 CKS1B (0.54) HIF1APYCR1DRD1TAAR1SMN1; SMN2
SCHEMBL6186299 0.73 HIF1A (0.42) HIF1AEPAS1ADRA2CCHRM2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6927228-B2 Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-09 US disclosed
EP-1309575-B1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2005-06-08 EP disclosed
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-26 US disclosed
EP-1309575-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS Galderma Research & Development (FR) 2003-05-14 EP disclosed
WO-2002012210-A9 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RES & DEV (FR) 2002-04-18 WO disclosed
WO-2002012210-A1 BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS GALDERMA RESEARCH & DEVELOPMENT (FR) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039038-A1 Biaromatic compound activators of PPARy-type receptors PPARG, PPARA, PPARD HIF1A 1331/4885EPAS1 563/4885PYCR1 538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.